Dec 16 (Reuters) - PureTech Health PLC :
* PURETECH’S DEUPIRFENIDONE (LYT-100) SLOWED LUNG FUNCTION DECLINE IN PEOPLE WITH IDIOPATHIC PULMONARY FIBROSIS $(IPF.UK)$ AS MEASURED BY FORCED VITAL CAPACITY $(FVC)$, ACHIEVING THE PRIMARY AND KEY SECONDARY ENDPOINTS IN THE ELEVATE IPF PHASE 2B TRIAL
* PURETECH’S DEUPIRFENIDONE (LYT-100) SLOWED LUNG FUNCTION DECLINE IN PEOPLE WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AS MEASURED BY FORCED VITAL CAPACITY (FVC), ACHIEVING THE PRIMARY AND KEY SECONDARY ENDPOINTS IN THE ELEVATE IPF PHASE 2B TRIAL
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.